STOK

Stoke Therapeutics, Inc. [STOK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

STOK Stock Summary

Top 10 Correlated ETFs

STOK


Top 10 Correlated Stocks

STOK


In the News

09:51 29 Mar 2024 STOK

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

06:10 29 Mar 2024 STOK

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.

09:51 29 Mar 2024 STOK

Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)

Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11:01 29 Mar 2024 STOK

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

01:37 29 Mar 2024 STOK

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.

02:31 29 Mar 2024 STOK

Triple Threat: 3 Stocks to Buy for 3X Upside Potential

You want speculative stocks with upside potential up to 3X returns? I'm going to give them to you.

10:56 29 Mar 2024 STOK

Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?

The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

08:01 29 Mar 2024 STOK

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

06:50 29 Mar 2024 STOK

New Strong Buy Stocks for February 14th

GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.

04:30 29 Mar 2024 STOK

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 6:45 p.m. ET (3:45 p.m. PT). A live audio webcast of the presentation will be available on the Investors & News section of Stoke's website.

STOK Financial details

Company Rating
Neutral
Market Cap
281.32M
Income
-95.54M
Revenue
9.25M
Book val./share
3.91
Cash/share
4.85
Dividend
-
Dividend %
-
Employees
117
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.46
Forward P/E
-5.74
PEG
7.1
P/S
25.64
P/B
1.36
P/C
2.78
P/FCF
-3.54
Quick Ratio
8.52
Current Ratio
9.13
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-2.23
EPS next Y
-2.35
EPS next Q
-0.65
EPS this Y
3.46%
EPS next Y
5.56%
EPS next 5Y
-5.38%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-233.33%
EPS Q/Q
-20.29%
-
-
-
-
SMA20
42.86%
SMA50
100%
SMA100
150%
Inst Own
85.43%
Inst Trans
0.78%
ROA
-40%
ROE
-50%
ROC
-0.5%
Gross Margin
100%
Oper. Margin
-1169%
Profit Margin
-1033%
Payout
-
Shs Outstand
46.3M
Shs Float
28.79M
-
-
-
-
Target Price
33.67
52W Range
3.35-14.0
52W High
-3.57%
52W Low
+350%
RSI
80
Rel Volume
19.93
Avg Volume
228.71K
Volume
4.56M
Perf Week
125.38%
Perf Month
156.17%
Perf Quarter
257.14%
Perf Half Y
247.04%
-
-
-
-
Beta
0.67
-
-
Volatility
3.2%, 2.53%
Prev Close
0%
Price
13.5
Change
-4.86%

STOK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.32
Net income per share
-0.53-1.59-1.51-2.31-2.39
Operating cash flow per share
-0.47-1.73-1.26-1.82-0.82
Free cash flow per share
-0.51-1.82-1.29-1.85-0.92
Cash per share
4.4812.388.585.985.9
Book value per share
4.4712.498.545.934.75
Tangible book value per share
4.4712.498.545.934.75
Share holders equity per share
4.4712.498.545.934.75
Interest debt per share
000.030.040.14
Market cap
601.2M508.95M2.07B881.38M359.02M
Enterprise value
495.8M286.48M1.79B737.99M247.83M
P/E ratio
-48.01-17.84-40.98-10.4-3.86
Price to sales ratio
000028.94
POCF ratio
-54.83-16.39-49.12-13.17-11.27
PFCF ratio
-50.52-15.57-47.93-12.94-10.02
P/B Ratio
5.722.277.254.051.94
PTB ratio
5.722.277.254.051.94
EV to sales
000019.98
Enterprise value over EBITDA
-39.45-8.03-33.68-8.57-2.37
EV to operating cash flow
-45.22-9.22-42.32-11.03-7.78
EV to free cash flow
-41.67-8.76-41.29-10.84-6.92
Earnings yield
-0.02-0.06-0.02-0.1-0.26
Free cash flow yield
-0.02-0.06-0.02-0.08-0.1
Debt to equity
0000.010.01
Debt to assets
0000.010.01
Net debt to EBITDA
8.396.245.411.671.07
Current ratio
43.0355.1225.7313.377.77
Interest coverage
000-717.21-33.43
Income quality
0.880.960.810.780.32
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00003.14
Research and developement to revenue
00006.27
Intangibles to total assets
00000
Capex to operating cash flow
0.090.050.020.020.12
Capex to revenue
0000-0.32
Capex to depreciation
-4.37-3.63-1.18-1.23-2.56
Stock based compensation to revenue
00001.84
Graham number
7.3221.1217.0417.5416
ROIC
-0.12-0.14-0.18-0.38-0.51
Return on tangible assets
-0.12-0.12-0.17-0.35-0.36
Graham Net
4.3812.158.235.414.22
Working capital
103.68M221.93M282.51M212.08M212.68M
Tangible asset value
105.07M224.43M286.08M217.78M184.85M
Net current asset value
103.67M221.71M282.08M208.13M172.85M
Invested capital
0000.010.01
Average receivables
98K238.5K143.5K69K360K
Average payables
606K911K1.12M1.94M1.58M
Average inventory
00005.47M
Days sales outstanding
000017.3
Days payables outstanding
0609.14283.32390.3779.09
Days of inventory on hand
00001.13K
Receivables turnover
000021.1
Payables turnover
00.61.290.944.61
Inventory turnover
00000.32
ROE
-0.12-0.13-0.18-0.39-0.5
Capex per share
-0.04-0.09-0.03-0.03-0.1

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.070.080.12-0.060.07
Net income per share
-0.61-0.56-0.43-0.69-0.55
Operating cash flow per share
-0.56-0.57-0.5-0.49-0.39
Free cash flow per share
-0.61-0.58-0.51-0.51-0.4
Cash per share
6.385.825.965.244.85
Book value per share
5.184.695.034.33.91
Tangible book value per share
5.184.695.034.33.91
Share holders equity per share
5.184.695.034.33.91
Interest debt per share
0.080.10.110.110.12
Market cap
506.16M363.98M354.33M469.72M174.41M
Enterprise value
395.07M252.78M166.39M280.11M-13.07M
P/E ratio
-5.26-4.13-4.84-3.83-1.78
Price to sales ratio
174.24111.3468.78-189.3352.72
POCF ratio
-22.95-16.27-16.59-21.55-10.1
PFCF ratio
-21.01-15.98-16.46-20.75-9.88
P/B Ratio
2.481.971.662.471.01
PTB ratio
2.481.971.662.471.01
EV to sales
13677.3332.3-112.9-3.95
Enterprise value over EBITDA
-14.76-9.3-6.74-8.420.48
EV to operating cash flow
-17.91-11.3-7.79-12.850.76
EV to free cash flow
-16.4-11.1-7.73-12.370.74
Earnings yield
-0.05-0.06-0.05-0.07-0.14
Free cash flow yield
-0.05-0.06-0.06-0.05-0.1
Debt to equity
0.010.010.010.010.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
4.154.097.615.76.88
Current ratio
9.197.778.5711.289.13
Interest coverage
-27.28-18.37-9.72-12.96-10.27
Income quality
0.840.870.950.710.7
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.422.871.98-4.123.1
Research and developement to revenue
6.926.443.81-8.286.13
Intangibles to total assets
00000
Capex to operating cash flow
0.090.020.010.040.02
Capex to revenue
-0.7-0.13-0.030.34-0.12
Capex to depreciation
-5.23-0.67-0.28-1.37-0.6
Stock based compensation to revenue
2.041.771.14-2.721.98
Graham number
8.447.686.988.26.98
ROIC
-0.12-0.12-0.08-0.15-0.13
Return on tangible assets
-0.09-0.09-0.06-0.12-0.1
Graham Net
4.534.174.493.853.46
Working capital
235.81M212.68M238.71M224.4M204.82M
Tangible asset value
204.14M184.85M213.82M190.2M173M
Net current asset value
191.12M172.85M202.26M179.51M163.13M
Invested capital
0.010.010.010.010.01
Average receivables
372.5K491.5K540K314K116K
Average payables
2.76M1.34M2.53M2.93M2.32M
Average inventory
05.47M10.56M10.57M10.94M
Days sales outstanding
12.2416.198.59-4.932.61
Days payables outstanding
186.1459.84337.32120230.7
Days of inventory on hand
0854.06799.64844.47820.2
Receivables turnover
7.355.5610.47-18.2434.46
Payables turnover
0.481.50.270.750.39
Inventory turnover
00.110.110.110.11
ROE
-0.12-0.12-0.09-0.16-0.14
Capex per share
-0.05-0.010-0.02-0.01

STOK Frequently Asked Questions

What is Stoke Therapeutics, Inc. stock symbol ?

Stoke Therapeutics, Inc. is a US stock , located in Bedford of Ma and trading under the symbol STOK

Is Stoke Therapeutics, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $31.5. The lowest prediction is $21 and the highest is $58

What is STOK stock prediction ?

With a median analyst target price of $21.5, 2 stock analysts have made 2 forecasts in last 90 days. $21 is the lowest and $22 is the greatest projection.

What is Stoke Therapeutics, Inc. stock quote today ?

Stoke Therapeutics, Inc. stock price is $13.5 today.

Is Stoke Therapeutics, Inc. stock public?

Yes, Stoke Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap